Cargando…

Effectiveness and Safety of Tofacitinib in the Management of Ulcerative Colitis: A Brazilian Observational Multicentric Study

BACKGROUND: Ulcerative colitis (UC) is a chronic inflammatory bowel disease which affects the colorectal mucosa with a relapsing–remitting pattern. The therapeutic options currently available for the medical management of UC include many options. Tofacitinib is an oral small molecule, Janus kinase (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perin, Ramir Luan, Magro, Daniela Oliveira, Andrade, Adriana Ribas, Argollo, Marjorie, Carvalho, Nayara Salgado, Damião, Adérson Omar Moura Cintra, Dotti, Adriana Zanoni, Ferreira, Sandro da Costa, Flores, Cristina, Ludvig, Juliano Coelho, Nones, Rodrigo Bremer, Queiroz, Natalia Sousa Freitas, Parra, Rogério Serafim, Steinwurz, Flavio, Teixeira, Fabio Vieira, Kotze, Paulo Gustavo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Observations and Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855307/ https://www.ncbi.nlm.nih.gov/pubmed/36777366 http://dx.doi.org/10.1093/crocol/otac050

Ejemplares similares

Vedolizumab in Mild-to-Moderate Crohn’s Disease Patients Naïve to Biological Therapy: A Multicentric Observational Study
por: Dotti, Adriana Zanoni, et al.
Publicado: (2023)

How to manage inflammatory bowel disease during the COVID-19 pandemic: A guide for the practicing clinician
por: Chebli, Júlio Maria Fonseca, et al.
Publicado: (2021)

Correlation of serum levels of anti-tumor necrosis factor agents with perianal fistula healing in Crohn’s disease: a narrative review
por: Miranda, Eron Fabio, et al.
Publicado: (2021)

Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn’s disease: a real-world multicenter Brazilian study
por: Parra, Rogério Serafim, et al.
Publicado: (2022)

Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program
por: Dubinsky, Marla C, et al.
Publicado: (2022)

Tofacitinib as a maintenance therapy in patients with ulcerative colitis stratified by OCTAVE Sustain baseline Mayo endoscopic subscore
por: Lee, Scott D., et al.
Publicado: (2023)

Risk stratification and geographical mapping of Brazilian inflammatory bowel disease patients during the COVID-19 outbreak: Results from a nationwide survey
por: Queiroz, Natália Sousa Freitas, et al.
Publicado: (2021)

Corticosteroid-free efficacy and safety outcomes in patients receiving tofacitinib in the OCTAVE Sustain maintenance study
por: Vavricka, Stephan R., et al.
Publicado: (2022)

Tofacitinib
Publicado: (2012)

Therapeutic Drug Monitoring of Biologics in IBD: Essentials for the Surgical Patient
por: Nones, Rodrigo Bremer, et al.
Publicado: (2021)

Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment
por: Sandborn, William J., et al.
Publicado: (2021)

Erratum to Tofacitinib
Publicado: (2012)

Serum levels of infliximab in Brazilian patients with Crohn's disease: what are the reasons for differences from previous studies?
por: Teixeira, Fabio Vieira, et al.
Publicado: (2019)

Bioequivalence of the pharmacokinetics between tofacitinib aspartate and tofacitinib citrate in healthy subjects
por: Shin, Wonsuk, et al.
Publicado: (2020)

Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19
por: Maslennikov, Roman, et al.
Publicado: (2021)

Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis
por: Rubin, David T., et al.
Publicado: (2021)

The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme
por: Farraye, Francis A., et al.
Publicado: (2021)

Effectiveness and Safety of Ustekinumab for Moderate to Severely Active Crohn’s Disease: Results from an Early Access Program in Brazil
por: Chebli, Julio Maria Fonseca, et al.
Publicado: (2022)

Tofacitinib is not a biologic
por: Marren, Amy S.
Publicado: (2017)

Predictive factors of response to infliximab therapy in Brazilian inflammatory bowel disease patients
por: Martins, Camilla de Almeida, et al.
Publicado: (2023)

VEXAS syndrome presenting as refractory cutaneous Kikuchi disease-like inflammatory pattern responding to tofacitinib
por: Fahmy, Lauren M., et al.
Publicado: (2023)

Comprehensive neuropsychological evaluation of children and adolescents with sickle cell anemia: a hospital-based sample
por: Nunes, Samantha, et al.
Publicado: (2017)

Unintentional Monotherapy in Rheumatoid Arthritis Patients Receiving Tofacitinib and Drug Survival Rate of Tofacitinib
por: Inanc, Nevsun, et al.
Publicado: (2023)

Intra-Esophageal pH Monitoring on Two Consecutive Days in Patients With Gastroesophageal Reflux Symptoms
por: Batista, Andrea de Oliveira, et al.
Publicado: (2019)

Tofacitinib for refractory uveitis and scleritis
por: Paley, Michael A., et al.
Publicado: (2018)

Treatment of Multiorgan Sarcoidosis With Tofacitinib
por: Damsky, William, et al.
Publicado: (2020)

Tofacitinib in Hypertrophic Lichen Planus
por: SEIRINGER, Peter, et al.
Publicado: (2020)

Treatment of granuloma annulare with tofacitinib
por: Bosch‐Amate, Xavier, et al.
Publicado: (2022)

Endoscopic activity, tissue factor and Crohn’s disease: findings in clinical remission patients
por: Andrade, Adriana Ribas, et al.
Publicado: (2020)

Temporal trends in the epidemiology of inflammatory bowel diseases in the public healthcare system in Brazil: A large population-based study
por: Quaresma, Abel B., et al.
Publicado: (2022)

Management of inflammatory bowel disease patients in the COVID-19 pandemic era: a Brazilian tertiary referral center guidance
por: Queiroz, Natália Sousa Freitas, et al.
Publicado: (2020)

Review of the epidemiology and burden of ulcerative colitis in Latin America
por: Kotze, Paulo Gustavo, et al.
Publicado: (2020)

The Role of Tofacitinib in the Management of Alopecia Totalis
por: Hernandez-Montoya, Carlos, et al.
Publicado: (2019)

Tofacitinib in patients with refractory Takayasu’s arteritis
por: Li, Jing, et al.
Publicado: (2020)

Topical tofacitinib in treatment of alopecia areata
por: Ferreira, Sineida Berbert, et al.
Publicado: (2020)

Effects of naringenin on the pharmacokinetics of tofacitinib in rats
por: Wang, Bo, et al.
Publicado: (2020)

Tofacitinib in Vogt-Koyanagi-Harada disease
por: Dutta Majumder, Parthopratim, et al.
Publicado: (2020)

Granulomatöse rosazeaartiges Exanthem unter Tofacitinib
por: Neumann, Kristina, et al.
Publicado: (2021)

Treatment of Resistant Alopecia areata with Tofacitinib
por: Avhad, Ganesh
Publicado: (2022)

Tofacitinib for the Treatment of Steroid-Induced Rosacea
por: Li, Tianhao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qeatl7t1hu1526rtg39ui32jh8